- Rating
- 2
- Confidence
- 3
- Informativeness
- 1
- Presentation
- 2
- Soundness
- 2
Read review
Paper summary
The paper studies the problem of de novo protein design given functional labels, e.g., GO terms. The authors propose to leverage the hierarchical nature of GO terms to provide an inductive bias for sharing information across related functions. To do so, they propose Ontology-Annealed Function Conditioning (OAFC), which anneals condition representations during denoising, and Common-Ancestor Relation Encoding, which encodes function pairs by their paths to the common ancestor on the ontology tree. Experimental results show gains on functional recovery and foldability metrics.
Critical strengths
- The proposed method is well-motivated. Modeling coarse-to-fine-grained functional labels in an annealing way during denoising is reasonable. Including common-ancestor relation encoding helps better model the relationship between functional terms.
Critical weaknesses
- The major concern is on experimental evaluation. The functional recovery benchmark heavily relies on a not-so-good GO predictor as an evaluation oracle and the improvement over CodeFP is marginal. This makes it questionable whether the benefits of the method are significant as claimed in real world. The generated sequences are only measured with a very permissive confidence threshold, without measuring the consistency with the generated structures.
- The second concerns is the incremental novelty relative to CodeFP. CodeFP already provides the main generator. The main additions introduced in the paper are OAFC and CARE for better hierarchical function conditioning modeling.
Questions for authors
- How trustworthy is DeepGO-SE as an oracle for function recovery metrics? It only achieves 0.554 Fmax for GO prediction benchmarks and the positive control of the paper itself shows the concerns as well: natural proteins achieve M1-Macro of only 0.522 in Table 1. Besides, the improvement of CodeFP2 over CodeFP on these metrics is very marginal.
- The foldability metrics only provide weak evidence of design quality. Usually, in de novo protein design literature, people use stricter thresholds for these metrics, e.g., ProteinGenerator uses AF2 pLDDT > 90 and scRMSD < 2A. The thresholds used in the benchmark are too permissive. Also, although the paper generates sequences and structures jointly, it does not evaluate the compatibility between them.
- The paper solely focuses on GO-conditioned generation. However, this is a very narrow conditioning scope that might be far from real-world protein design need. Some GO terms specify meaningful enzymatic reactions. But it is hard to design binders for specific unseen target if the model only supports GO conditioning.
4 comments
Response to Reviewer CAvC (Part 2/2: Novelty and biological value)
3. W2: A generative paradigm for functional protein design.
Our key insight in functional protein design is to make functional specificity part of the generation trajectory: broad functional context guides early states, while precise activity constraints gain emphasis as sequence and structure become resolved. This insight is motivated by two observations. First, protein functional hierarchies have a biological basis: enolase-superfamily enzymes share a catalytic step yet catalyze different reactions (Babbitt et al., Biochemistry, 1996); finer specialization corresponds to additional conserved molecular features (Holliday et al., Database, 2017). Second, conditional image-diffusion studies show that semantic guidance has stage-dependent effects (Görgün et al., ICLR, 2026).
We therefore use functional hierarchy as an inductive bias for functional protein generation. OAFC implements coarse-to-specific guidance for fixed target functions, as an increasingly resolved scaffold should better support precise activity requirements. CARE extends this inductive bias to joint conditioning by encoding hierarchical paths among co-requested functions.
The ablations support the effectiveness of this generative paradigm. Under matched training (Table 3), replacing OAFC with static hierarchy pooling reduces HS/ER from 0.420/0.199 to 0.373/0.159. With the checkpoint fixed, coarse-to-specific guidance improves HS over static guidance, while reversing the main progression lowers HS (Figure 3). Removing CARE paths while retaining endpoint-pair embeddings reduces HS/ER to 0.407/0.190 (Table 3), supporting the value of hierarchical relations among functions.
4. Q3: Biological value of GO-conditioned design.
GO molecular-function terms describe activities performed by proteins, including catalysis, molecular binding, membrane transport, receptor activity, and regulation of enzyme or transcriptional activity. They specify required capabilities without fixing a sequence or scaffold, supporting exploration of different molecular realizations. Combining terms can further specify multiple requirements, such as recognizing a protein class and activating its enzymatic activity.
Experimentally validated designs illustrate why such functional objectives matter:
| Designed protein | Practical design objective | Core functional requirements expressible with GO-MF |
|---|---|---|
| Hsp70 activator (Cell Chemical Biology, 2025) | Modulate chaperone activity for protein refolding and targeted condensate perturbation | Hsp70 protein binding (GO:0030544) and ATPase activator activity (GO:0001671): specify the target class and the desired regulatory activity |
| LuxSit luciferase (Nature, 2023) | Develop bioluminescent tools for cellular reporting and imaging | Luciferin monooxygenase activity (GO:0045289): specify the light-producing catalytic activity |
| De novo voltage-gated anion channels, dVGACs (Cell, 2025) | Engineer synthetic ion channels with tunable properties for suppressing neuronal firing | Voltage-gated monoatomic anion channel activity (GO:0008308): specify voltage-dependent anion transport |
These examples span catalysis, regulation of protein function, and voltage-dependent ion transport. The Hsp70 example illustrates the value of combining functions: binding alone does not specify whether the protein should activate or inhibit its partner.
Designing a binder against a specified unseen target is outside our current task and requires additional target/interface information. Binding is one functional objective within a broader design space. GO provides a standardized vocabulary for specifying many other activities and their combinations, allowing design objectives to express both molecular recognition and the desired catalytic, transport or regulatory effect.
Thank you for the detailed response and additional experiments. They provide useful evidence of improvement over CodeFP, but my main concerns remain.
1. Reliability of predictor-based functional evaluation.
My concern is about whether current function predictors are sufficiently reliable to establish functional success for newly designed proteins, particularly those with hypothetical OOD function combinations. Citing their use in other benchmarks does not resolve this question.
To give some numbers, ProteInfer reports an all-GO F1 of 0.885 on a random Swiss-Prot split; TransFew reports molecular-function Fmax of 0.6655 on Test_all and 0.6476 on its low-sequence-similarity Test_novel split; FunBind reports molecular-function Fmax of 0.699 with multimodal inputs and 0.663 using sequence alone. Most of them are still far from a perfect GO prediction oracle to use.
The agreement across four evaluators strengthens the evidence for improvements in predictor scores. However, the connection to actual biological activity remains unverified.
2. Absolute quality of the generated sequence–structure pairs.
The additional structural evaluations reinforce my concern about the absolute quality of the designs. On the full test set, only 17.75% achieve pLDDT >90 and 47.11% achieve pTM ≥0.8. More critically, only 11.18% achieve Cα scRMSD <2 Å, and 4.01% satisfy both scRMSD <2 Å and pLDDT >90, which are far from the current state-of-the-art protein design methods.
For context, La-Proteina reports 72.2% Cα co-designability using ESMFold and an scRMSD <2 Å criterion on jointly generated sequences and structures, without sequence redesign. The different tasks and datasets do not lead to a direct comparison, but the result motivates comparison with stronger contemporary co-design baselines.
3. Demonstrated value of GO-conditioned design.
I agree that the activities represented by GO terms have biological value. My question concerns whether the proposed method can produce useful proteins with those activities, and what practical benefit its conditioning provides.
For example, the cited Hsp70 study already used target-site-conditioned Rosetta design to generate binders, followed by experimental characterization that distinguished activators from inhibitors. This demonstrates an existing route to the stated objective. Modern tools such as RFdiffusion3/RFD4-Proteina likewise support binder generation conditioned on target structures and binding-site information, although binding alone does not establish activation.
Could the authors demonstrate one concrete application within their stated scope where GO conditioning produces the intended activity, and compare it with an appropriate existing design workflow while accounting for differences in available input information? Describing published functional proteins using GO terms does not establish that this model can generate comparable functional designs.
Follow-up response to Reviewer CAvC
Thank you for the follow-up.
1. W1 / Q1. Biological evidence for predicted functions.
DeepGO-SE predictions have biological support. DeepGO-SE predicted phosphodiesterase activity for human FAM151B (score .846), in agreement with neXtProt experts. Kulmanov et al. (Nature Machine Intelligence, 2024) then searched for proteins structurally similar to FAM151B. They identified GDPD3, which has low sequence identity to FAM151B and experimental evidence for the predicted activity.
Two Natural OOD examples. DeepGO-SE recovered NAD-dependent malate dehydrogenase activity and NAD binding in two of five designs. HAMAP and NCBIfam identified both as malate dehydrogenases. The designs conserved 7/8 and 8/8 of the residues examined in the malate dehydrogenase reference structure. For a 392-residue design, DeepGO-SE recovered D-amino-acid dehydrogenase activity and nucleotide binding, and Pfam detected an FAD-dependent oxidoreductase domain across residues 4–372.
2. W1 / Q2. Functional recovery and sequence–structure consistency.
Prompteina (Lee et al., arXiv, Oct. 2026) extends Proteina-Complexa with text-conditioned flow matching. We used GO names and definitions for the same 8,309 requests. Function and confidence use the original CodeFP/CodeFP2 designs. DeepGO-SE scores cover the same 8,279 eligible requests for all models. For consistency, we matched lengths across models and compared each co-designed structure with the ESMFold-v1 refold of its paired sequence (four recycles).
| Full test | CodeFP | CodeFP2 | Prompteina |
|---|---|---|---|
| HS / min-HS | .4473 / .3731 | .4659 / .3951 | .1978 / .1371 |
| Exact recovery (ER) | .2586 | .2783 | .04146 |
| pLDDT >90 | 13.37% | 17.75% | 6.43% |
| pTM ≥0.8 | 39.44% | 47.11% | 74.14% |
| Mean scTM | .6645 | .6996 | .8860 |
| Full-chain Cα scRMSD <2 Å | 9.76% | 11.18% | 56.90% |
| scRMSD <2 Å and pLDDT >90 | 3.51% | 4.01% | 5.91% |
CodeFP2 achieves 6.7× Prompteina’s GO-macro exact recovery and more often reaches pLDDT >90 (17.75% vs 6.43%). For scRMSD <2 Å, CodeFP2 and Prompteina pass at 11.18% and 56.90%, respectively. Adding pLDDT >90 gives 4.01% and 5.91%. Prompteina’s stronger co-design consistency accompanies lower functional recovery. Differences in backbone and training may contribute to the consistency gap. On their shared DPLM-2 backbone, CodeFP2 improves on CodeFP across all reported structural metrics, supporting the structural benefit of our generative paradigm.
3. Q3. Catalytic and structural design objectives.
Coenzyme Q synthesis. Some animal coenzyme Q (CoQ) enzymes are unstable in isolation. Nicoll et al. (Nature Catalysis, 2024) used ancestral enzymes from known families to reconstitute the pathway in vitro. In bacteria, UbiG (Zhu et al., 2015) uses S-adenosylmethionine (SAM) to methylate CoQ intermediates at two steps.
Our Natural OOD request captures this chemistry. “Methyltransferase activity” specifies the reaction class, and “SAM-dependent methyltransferase activity” adds the donor. Together they leave the substrate and enzyme family open. We compared five designs per method, matching Prompteina to the CodeFP2 lengths. DeepGO-SE recovered both terms in 5/5 CodeFP2, 5/5 CodeFP and 3/5 Prompteina designs.
In a post hoc family screen, the HAMAP and NCBIfam UbiG profiles both matched just one of the 15 designs (1/5 CodeFP2, 0/5 CodeFP, 0/5 Prompteina). The CodeFP2 candidate retains all four annotated SAM-binding residues and 14/18 residues contacting the cofactor product in the UbiG crystal structure. This makes CoQ intermediates plausible substrates to test. The candidate shares only 62.3% sequence identity with its closest training hit across the aligned region.
Hydrogel lenses. Polymer mimics (Langmuir, 2017) matched β-crystallin’s refractive index. In lens fabrication trials (MIT PhD thesis, 2025), 13 squid S-crystallins were prone to precipitation, motivating new sequences that combine refractivity and solubility.
GO:0005212 specifies a structural role in the eye lens. Binding a chosen target does not specify a material’s refractive properties. Across all 17 full-test requests for this term alone, 16/17 CodeFP2 and 0/17 Prompteina designs recovered the term and matched a β/γ-crystallin domain (PF00030). Over all 17 designs per model, median TM-scores for the generated structures against human γD-crystallin (PDB 1HK0) were .727 and .310, respectively (173-residue reference normalization).
Response to Reviewer CAvC (Part 1/2: Evaluation)
Thank you for the feedback. We address the evaluation, novelty and biological relevance below. We will incorporate these clarifications and additional results into the revised manuscript.
1. W1 / Q1: Functional evaluation and OOD gains.
DeepGO-SE is an established computational evaluator for functional protein design, used for functional evaluation in the PDFBench benchmark (ICML 2026). Its original study (Nature Machine Intelligence, 2024) demonstrated improvements over the evaluated baselines on benchmarks with experimentally supported annotations and sequence-similarity-controlled splits, with additional evaluation against expert-curated neXtProt predictions and corroboration through structural homologues.
To assess consistency across evaluators, we also use three other published protein-function predictors on full-test and OOD generations: ProteInfer (eLife, 2023), TransFew (Bioinformatics Advances, 2024), and FunBind (Bioinformatics, 2026), with fixed thresholds.
ER measures exact requested-function recovery. HS also credits broader ancestor matches, with credit decreasing with hierarchical distance. Both are GO-macro averages. min-HS averages each candidate's weakest target score. CodeFP2 achieves consistent gains in functional recovery across evaluators, with substantial improvements on OOD combinations. Across all four evaluators, OOD exact recovery improves by 21.6%–33.3% on Natural OOD and 35.8%–59.1% on Hypothetical OOD, relative to CodeFP.
Entries are CodeFP → CodeFP2:
Expanded original-protocol baseline comparisons are in our response to Reviewer SCqL, W2.1–W2.2.
2. W1 / Q2: Stricter foldability and sequence–structure consistency.
Beyond the original pLDDT ≥70/pTM ≥0.5 screening, stricter ESMFold confidence passing rates are CodeFP → CodeFP2 (%):
We also measure compatibility between co-designed sequences and structures on the full test set:
scTM/scRMSD compare generated structures with ESMFold predictions of their paired sequences; confidence scores use ESMFold.
CodeFP2 consistently improves structural confidence across thresholds and test sets, alongside better sequence–structure compatibility.